Imaging and nanomedicine for diagnosis and therapy in the central nervous system

Report of the eleventh annual blood-brain barrier disruption consortium meeting

Leslie Muldoon, Paul Tratnyek, P. M. Jacobs, Nancy Doolittle, G. A. Christoforidis, J. A. Frank, M. Lindau, P. R. Lockman, S. P. Manninger, Y. Qiang, A. M. Spence, S. I. Stupp, M. Zhang, Edward Neuwelt

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The blood-brain barrier (BBB) presents a major obstacle to the treatment of malignant brain tumors and other central nervous system (CNS) diseases. The Eleventh Annual Blood-Brain Barrier Disruption Consortium Meeting was convened to discuss recent advances and future directions in imaging and nanomedicine. Two sessions, one on Cell and Molecular Imaging in the CNS and another on Nanotechnology, Nanobiology, and Nanomedicine, were held March 17-18, 2005, in Portland, Ore. CNS imaging presentations targeted differentiating tumor, neural lesions, and necrosis from healthy brain tissue; methods of delivery of imaging agents across the BBB; and new iron oxide-based nanoparticle contrast agents for MR imaging. Nanobiology presentations covered the development of new nanotechnology and its use in imaging, diagnosis, and therapy in the CNS. Discussions at this meeting stressed the role of biotechnology in the convergence of CNS imaging and nanomedicine and are summarized in this article.

Original languageEnglish (US)
Pages (from-to)715-721
Number of pages7
JournalAmerican Journal of Neuroradiology
Volume27
Issue number3
StatePublished - Mar 2006

Fingerprint

Nanomedicine
Annual Reports
Blood-Brain Barrier
Central Nervous System
Nanotechnology
Molecular Imaging
Central Nervous System Diseases
Therapeutics
Biotechnology
Brain Neoplasms
Nanoparticles
Contrast Media
Necrosis
Brain
Neoplasms

ASJC Scopus subject areas

  • Clinical Neurology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Imaging and nanomedicine for diagnosis and therapy in the central nervous system : Report of the eleventh annual blood-brain barrier disruption consortium meeting. / Muldoon, Leslie; Tratnyek, Paul; Jacobs, P. M.; Doolittle, Nancy; Christoforidis, G. A.; Frank, J. A.; Lindau, M.; Lockman, P. R.; Manninger, S. P.; Qiang, Y.; Spence, A. M.; Stupp, S. I.; Zhang, M.; Neuwelt, Edward.

In: American Journal of Neuroradiology, Vol. 27, No. 3, 03.2006, p. 715-721.

Research output: Contribution to journalArticle

Muldoon, L, Tratnyek, P, Jacobs, PM, Doolittle, N, Christoforidis, GA, Frank, JA, Lindau, M, Lockman, PR, Manninger, SP, Qiang, Y, Spence, AM, Stupp, SI, Zhang, M & Neuwelt, E 2006, 'Imaging and nanomedicine for diagnosis and therapy in the central nervous system: Report of the eleventh annual blood-brain barrier disruption consortium meeting', American Journal of Neuroradiology, vol. 27, no. 3, pp. 715-721.
Muldoon, Leslie ; Tratnyek, Paul ; Jacobs, P. M. ; Doolittle, Nancy ; Christoforidis, G. A. ; Frank, J. A. ; Lindau, M. ; Lockman, P. R. ; Manninger, S. P. ; Qiang, Y. ; Spence, A. M. ; Stupp, S. I. ; Zhang, M. ; Neuwelt, Edward. / Imaging and nanomedicine for diagnosis and therapy in the central nervous system : Report of the eleventh annual blood-brain barrier disruption consortium meeting. In: American Journal of Neuroradiology. 2006 ; Vol. 27, No. 3. pp. 715-721.
@article{3b559253bd114d5abf8157b019d6c183,
title = "Imaging and nanomedicine for diagnosis and therapy in the central nervous system: Report of the eleventh annual blood-brain barrier disruption consortium meeting",
abstract = "The blood-brain barrier (BBB) presents a major obstacle to the treatment of malignant brain tumors and other central nervous system (CNS) diseases. The Eleventh Annual Blood-Brain Barrier Disruption Consortium Meeting was convened to discuss recent advances and future directions in imaging and nanomedicine. Two sessions, one on Cell and Molecular Imaging in the CNS and another on Nanotechnology, Nanobiology, and Nanomedicine, were held March 17-18, 2005, in Portland, Ore. CNS imaging presentations targeted differentiating tumor, neural lesions, and necrosis from healthy brain tissue; methods of delivery of imaging agents across the BBB; and new iron oxide-based nanoparticle contrast agents for MR imaging. Nanobiology presentations covered the development of new nanotechnology and its use in imaging, diagnosis, and therapy in the CNS. Discussions at this meeting stressed the role of biotechnology in the convergence of CNS imaging and nanomedicine and are summarized in this article.",
author = "Leslie Muldoon and Paul Tratnyek and Jacobs, {P. M.} and Nancy Doolittle and Christoforidis, {G. A.} and Frank, {J. A.} and M. Lindau and Lockman, {P. R.} and Manninger, {S. P.} and Y. Qiang and Spence, {A. M.} and Stupp, {S. I.} and M. Zhang and Edward Neuwelt",
year = "2006",
month = "3",
language = "English (US)",
volume = "27",
pages = "715--721",
journal = "American Journal of Neuroradiology",
issn = "0195-6108",
publisher = "American Society of Neuroradiology",
number = "3",

}

TY - JOUR

T1 - Imaging and nanomedicine for diagnosis and therapy in the central nervous system

T2 - Report of the eleventh annual blood-brain barrier disruption consortium meeting

AU - Muldoon, Leslie

AU - Tratnyek, Paul

AU - Jacobs, P. M.

AU - Doolittle, Nancy

AU - Christoforidis, G. A.

AU - Frank, J. A.

AU - Lindau, M.

AU - Lockman, P. R.

AU - Manninger, S. P.

AU - Qiang, Y.

AU - Spence, A. M.

AU - Stupp, S. I.

AU - Zhang, M.

AU - Neuwelt, Edward

PY - 2006/3

Y1 - 2006/3

N2 - The blood-brain barrier (BBB) presents a major obstacle to the treatment of malignant brain tumors and other central nervous system (CNS) diseases. The Eleventh Annual Blood-Brain Barrier Disruption Consortium Meeting was convened to discuss recent advances and future directions in imaging and nanomedicine. Two sessions, one on Cell and Molecular Imaging in the CNS and another on Nanotechnology, Nanobiology, and Nanomedicine, were held March 17-18, 2005, in Portland, Ore. CNS imaging presentations targeted differentiating tumor, neural lesions, and necrosis from healthy brain tissue; methods of delivery of imaging agents across the BBB; and new iron oxide-based nanoparticle contrast agents for MR imaging. Nanobiology presentations covered the development of new nanotechnology and its use in imaging, diagnosis, and therapy in the CNS. Discussions at this meeting stressed the role of biotechnology in the convergence of CNS imaging and nanomedicine and are summarized in this article.

AB - The blood-brain barrier (BBB) presents a major obstacle to the treatment of malignant brain tumors and other central nervous system (CNS) diseases. The Eleventh Annual Blood-Brain Barrier Disruption Consortium Meeting was convened to discuss recent advances and future directions in imaging and nanomedicine. Two sessions, one on Cell and Molecular Imaging in the CNS and another on Nanotechnology, Nanobiology, and Nanomedicine, were held March 17-18, 2005, in Portland, Ore. CNS imaging presentations targeted differentiating tumor, neural lesions, and necrosis from healthy brain tissue; methods of delivery of imaging agents across the BBB; and new iron oxide-based nanoparticle contrast agents for MR imaging. Nanobiology presentations covered the development of new nanotechnology and its use in imaging, diagnosis, and therapy in the CNS. Discussions at this meeting stressed the role of biotechnology in the convergence of CNS imaging and nanomedicine and are summarized in this article.

UR - http://www.scopus.com/inward/record.url?scp=33745903890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745903890&partnerID=8YFLogxK

M3 - Article

VL - 27

SP - 715

EP - 721

JO - American Journal of Neuroradiology

JF - American Journal of Neuroradiology

SN - 0195-6108

IS - 3

ER -